Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively (Q79614913)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

title

Home treatment with Elaprase and Naglazyme is safe in patients with mucopolysaccharidoses types II and VI, respectively (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

author name string

S Bagewadi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

J Roberts

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

J Mercer

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

S Jones

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

J Stephenson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

J E Wraith

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

publication date

19 October 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

number of pages

5

1 reference

Journal of Inherited Metabolic Disease

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

24 December 2019

page(s)

733-737

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18923918%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10545-008-0980-0

24 December 2019

exact match

0 references

cites work

Home treatment with enzyme replacement therapy for mucopolysaccharidosis type I is feasible and safe

1 reference

12 December 2020

Intravenous enzyme replacement therapy: better in home or hospital?

1 reference

12 December 2020

Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, o

1 reference

12 December 2020

A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)

1 reference

12 December 2020

Home therapy for lysosomal storage disorders

1 reference

12 December 2020